139 results on '"Straka, Robert J."'
Search Results
102. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting
103. The effect of IL6-174C/G polymorphism on postprandial triglyceride metabolism in the GOLDN study*
104. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment
105. Abstract 908: In Vivo Role of the Pharmacogenetics of Glucuronidation in the Disposition and Triglyceride Response to Fenofibrate
106. Interleukin1β Genetic Polymorphisms Interact with Polyunsaturated Fatty Acids to Modulate Risk of the Metabolic Syndrome , ,3
107. The −256T>C Polymorphism in the Apolipoprotein A-II Gene Promoter Is Associated with Body Mass Index and Food Intake in the Genetics of Lipid Lowering Drugs and Diet Network Study
108. Fenofibrate Effect on Triglyceride and Postprandial Response of Apolipoprotein A5 Variants
109. Economic impacts attributable to the early clinical benefit of atorvastatin therapy – a US managed care perspective
110. Determination of Fenofibric Acid Concentrations by HPLC After Anion Exchange Solid-Phase Extraction From Human Serum
111. Mixture Models and Subpopulation Classification: A Pharmacokinetic Simulation Study and Application to Metoprolol CYP2D6 Phenotype
112. Evaluation of the Influence of Diabetes Mellitus on Antipyrine Metabolism and CYP1A2 and CYP2D6 Activity
113. Genetic Risk Scores Associated with Baseline Lipoprotein Subfraction Concentrations Do Not Associate with Their Responses to Fenofibrate.
114. QTc‐Interval Prolongation Associated with Slow Intravenous Erythromycin Lactobionate Infusions in Critically Ill Patients: A Prospective Evaluation and Review of the Literature
115. Antihypertensive Drug Use in the Long‐Term Care Facility: A Pilot Study and Review of the Literature
116. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota*
117. Pharmacogenomics of high-density lipoproteincholesterol-raising therapies.
118. The Clinical Significance of the Pharmacogenetics of Cardiovascular Medications
119. Determination of Dextromethorphan and Its O-Demethylated Metabolite from Urine
120. WDTC1, the Ortholog of Drosophila Adipose Gene, Associates With Human Obesity, Modulated by MUFA Intake.
121. The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions.
122. lnterleukinlj3 Genetic Polymorphisms Interact with Polyunsaturated Fatty Acids to Modulate Risk of the Metabolic Syndrome.
123. Improved Selectivity of a High-Performance Liquid Chromatography Assay for Debrisoquine and Its 4-Hydroxy Metabolite from Urine
124. Analysis of metoprolol enantiomers in human serum by liquid chromatography on a cellulose-based chiral stationary phase
125. Revised NCEP Guidelines for the Management of Hypercholesterolemia: An Overview.
126. Rare PPARAvariants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study
127. The Effect of CYP7A1Polymorphisms on Lipid Responses to Fenofibrate
128. Calcium channel antagonists: Morbidity and mortality--what's the evidence?
129. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota*.
130. Assessment of Hypercholesterolemia Control in a Managed Care Organization
131. Nonlinear Pharmacokinetics of Unbound Propranolol after Oral Administration
132. Improved Selectivity of a HighPerformance Liquid Chromatography Assay for Debrisoquine and Its 4Hydroxy Metabolite from Urine
133. Advancing pharmacogenomic research in US Hmong populations: prevalence of key single nucleotide variations in California Hmong.
134. Development and validation of the pharmacological statin-associated muscle symptoms risk stratification (PSAMS-RS) score using real-world electronic health record data.
135. Development and Application of Pharmacological Statin-Associated Muscle Symptoms Phenotyping Algorithms Using Structured and Unstructured Electronic Health Records Data.
136. Fenofibrate and metabolic syndrome.
137. WDTC1, the ortholog of Drosophila adipose gene, associates with human obesity, modulated by MUFA intake.
138. Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states.
139. The -256T>C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.